Nurix Therapeutics (NRIX) Projected to Announce Earnings on Thursday

Nurix Therapeutics (NASDAQ:NRIX) is anticipated to issue its Q3 2026 results after the market closes on Thursday, October 8th. Analysts expect the company to announce earnings of ($0.6009) per share and revenue of $24.3480 million for the quarter. Parties may visit the the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Thursday, October 15, 2026 at 4:00 PM ET.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). The company had revenue of $9.04 million during the quarter, compared to analyst estimates of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nurix Therapeutics Price Performance

Shares of NRIX stock opened at $22.60 on Wednesday. The firm has a market cap of $2.35 billion, a PE ratio of -6.55 and a beta of 1.82. The company has a 50-day moving average of $25.30 and a two-hundred day moving average of $20.74. Nurix Therapeutics has a 1-year low of $9.00 and a 1-year high of $28.23.

Insider Activity

In related news, CFO Hans van Houte sold 4,761 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $24.36, for a total transaction of $115,977.96. Following the sale, the chief financial officer directly owned 40,166 shares in the company, valued at approximately $978,443.76. This represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 4,356 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $25.00, for a total transaction of $108,900.00. Following the completion of the sale, the insider directly owned 117,227 shares in the company, valued at approximately $2,930,675. This trade represents a 3.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 21,372 shares of company stock valued at $518,463 in the last quarter. Company insiders own 6.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Truist Financial boosted their price target on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, July 10th. BTIG Research reiterated a “buy” rating and issued a $32.00 target price on shares of Nurix Therapeutics in a report on Friday, July 10th. HC Wainwright lifted their target price on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, July 10th. Oppenheimer began coverage on Nurix Therapeutics in a research report on Monday, June 29th. They issued an “outperform” rating and a $28.00 target price on the stock. Finally, Wall Street Zen upgraded Nurix Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $34.21.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.